Impact of delivery systems on siRNA immune activation and RNA interference

Immunology Letters

Volumn 141, Issue 2, 2012, Pages 169-180

  Forsbach, Alexandra ^a   Müller, Christian ^a   Montino, Carmen ^a   Kritzler, Andrea ^a   Curdt, Rainer ^a   Benahmed, Amina ^a   Jurk, Marion ^a   Vollmer, Jörg ^a  

^a PFIZER INC   (United States)

Author keywords

Combination RNAi and immune activation; Delivery systems; Immune response; SiRNA

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 1,3 DI OLEOYLOXY 2 (6 CARBOXY SPERMYL) PROPYLAMID; COMPLEMENTARY RNA; DHARMAFECT 1; DRUG CARRIER; HIPERFECT; JETPEI; LIPOFECTAMINE; POLYAMIDOAMINE; POLYETHYLENEIMINE; POLYLYSINE; PREDNICARBATE; SMALL INTERFERING RNA; SUPERFECT; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG FORMULATION; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; MALE; NONVIRAL GENE DELIVERY SYSTEM; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; RNA INTERFERENCE; RNA SEQUENCE;

BASE SEQUENCE; CELL LINE; CYTOKINES; GENETIC VECTORS; HUMANS; IMMUNITY, INNATE; IMMUNIZATION; LEUKOCYTES, MONONUCLEAR; MOLECULAR SEQUENCE DATA; NF-KAPPA B; NUCLEOTIDE MOTIFS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 84855917458     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.10.001     Document Type: Article

References (60)

1. Thomas T., Borkhardt A. Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy. Mol Interventions 2002, 58-167.
2. Tuschl T. RNA interference and small interfering RNAs. Chembiochem 2001, 2:239-245.
3. Czauderna F., Fechtner M., Dames S., Aygun H., Klippel A., Pronk G.J., et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003, 31:2705-2716.
4. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
5. Meister G., Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004, 431:343-349.
6. Gregory R.I., Chendrimada T.P., Cooch N., Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005, 123:631-640.
7. Hannon G.J., Rossi J.J. Unlocking the potential of the human genome with RNA interference. Nature 2004, 431:371-378.
8. Kim D.H., Behlke M.A., Rose S.D., Chang M.S., Choi S., Rossi J.J. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005, 23:222-226.
9. Kariko K., Bhuyan P., Capodici J., Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol 2004, 172:6545-6549.
10. Kim D.H., Longo M., Han Y., Lundberg P., Cantin E., Rossi J.J. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 2004, 22:321-325.
11. Hornung V., Guenthner-Biller M., Bourquin C., Ablasser A., Schlee M., Uematsu S., et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005, 11:263-270.
12. Judge A.D., Sood V., Shaw J.R., Fang D., McClintock K., Maclachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005, 23:457-462.
13. Sioud M. On the delivery of small interfering RNAs into mammalian cells. Expert Opin Drug Deliv 2005, 2:639-651.
14. Sioud M. Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2'-hydroxyl uridines in immune responses. Eur J Immunol 2006, 36:1222-1230.
15. Judge A., Maclachlan I. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 2008, 19:111-124.
16. Robbins M., Judge A., Ambegia E., Choi C., Yaworski E., Palmer L., et al. Misinterpreting the therapeutic effects of siRNA caused by immune stimulation. Hum Gene Ther 2008.
17. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 2005, 348:1079-1090.
18. Takahasi K., Yoneyama M., Nishihori T., Hirai R., Kumeta H., Narita R., et al. Nonself RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune responses. Mol Cell 2008, 29:428-440.
19. Marques J.T., Devosse T., Wang D., Zamanian-Daryoush M., Serbinowski P., Hartmann R., et al. A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol 2006, 24:559-565.
20. Hornung V., Ellegast J., Kim S., Brzozka K., Jung A., Kato H., et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997.
21. Schlee M., Roth A., Hornung V., Hagmann C.A., Wimmenauer V., Barchet W., et al. Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 2009, 31:25-34.
22. Ablasser A., Poeck H., Anz D., Berger M., Schlee M., Kim S., et al. Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J Immunol 2009, 182:6824-6833.
23. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303:1526-1529.
24. Forsbach A., Nemorin J., Völp K., Samulowitz U., Montino C., Müller C., et al. Characterization of conserved viral leader RNA sequences that stimulate innate immunity through TLRs. Oligonucleotides 2007, 17:405-417.
25. Forsbach A., Nemorin J.G., Montino C., Muller C., Samulowitz U., Vicari A.P., et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol 2008, 180:3729-3738.
26. Gorden K.B., Gorski K.S., Gibson S.J., Kedl R.M., Kieper W.C., Qiu X., et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005, 174:1259-1268.
27. Gorski K.S., Waller E.L., Bjornton-Severson J., Hanten J.A., Riter C.L., Kieper W.C., et al. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol 2006, 18:1115-1126.
28. Khairuddin N., Gantier M.P., Blake S.J., Wu S.Y., Behlke M.A., Williams B.R., et al. siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol 2011.
29. Jurk M., Heil F., Vollmer J., Schetter C., Krieg A.M., Wagner H., et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002, 3:499.
30. Jurk M., Kritzler A., Schulte B., Tluk S., Schetter C., Krieg A.M., et al. Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. Eur J Immunol 2006, 36:1815-1826.
31. Jurk M., Kritzler A., Debelak H., Vollmer J., Krieg A.M., Uhlmann E. Structure-activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists. ChemMedChem 2006, 1:1007-1014.
32. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168:4531-4537.
33. Ito T., Amakawa R., Kaisho T., Hemmi H., Tajima K., Uehira K., et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002, 195:1507-1512.
34. Zarember K.A., Godowski P.J. Tissue expression of human toll-like receptors and differential regulation of toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002, 168:554-561.
35. Peng G., Guo Z., Kiniwa Y., Voo K.S., Peng W., Fu T., et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005, 309:1380-1384.
36. Kokkinopoulos I., Jordan W.J., Ritter M.A. Toll-like receptor mRNA expression patterns in human dendritic cells and monocytes. Mol Immunol 2005, 42:957-968.
37. Ghosh T.K., Mickelson D.J., Solberg J.C., Lipson K.E., Inglefield J.R., Alkan S.S. TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha. Int Immunopharmacol 2007, 7:1111-1121.
38. Borawski J., Lindeman A., Buxton F., Labow M., Gaither L.A. Optimization procedure for small interfering RNA transfection in a 384-well format. J Biomol Screen 2007, 12:546-559.
39. Massoumi R., Chmielarska K., Hennecke K., Pfeifer A., Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006, 125:665-677.
40. Roth J., Dobbelstein M., Freedman D.A., Shenk T., Levine A.J. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 1998, 17:554-564.
41. Sioud M., Sorensen D.R. Systemic delivery of synthetic siRNAs. Methods Mol Biol 2004, 252:515-522.
42. Martin D.A., Siegel R.M., Zheng L., Lenardo M.J. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHalpha1) death signal. J Biol Chem 1998, 273:4345-4349.
43. Martinez A., Yang W.J., Chen X.C., Love C.M., Jin L., Glasebrook A., et al. Small interfering rna molecules as potential anti-human hepatitis C virus agents: identification and characterization of two siRNA molecules highly conserved in the major genotypes of the virus. Preclinica 2003, 1:274-283.
44. Vollmer J., Tluk S., Schmitz C., Hamm S., Jurk M., Forsbach A., et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves toll-like receptors 7 and 8. J Exp Med 2005, 202:1575-1585.
45. Judge A.D., Robbins M., Tavakoli I., Levi J., Hu L., Fronda A., et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009, 119:661-673.
46. Poeck H., Besch R., Maihoefer C., Renn M., Tormo D., Morskaya S.S., et al. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 2008.
47. Heil F., Ahmad-Nejad P., Hemmi H., Hochrein H., Ampenberger F., Gellert T., et al. The toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003, 33:2987-2997.
48. Hornung V., Schlender J., Guenthner-Biller M., Rothenfusser S., Endres S., Conzelmann K.K., et al. Replication-dependent potent IFN-alpha induction in human plasmacytoid dendritic cells by a single-stranded RNA virus. J Immunol 2004, 173:5935-5943.
49. Hassane F.S., Ivanova G.D., Bolewska-Pedyczak E., Abes R., Arzumanov A.A., Gait M.J., et al. A peptide-based dendrimer that enhances the splice-redirecting activity of PNA conjugates in cells. Bioconjug Chem 2009, 20:1523-1530.
50. Zamanian-Daryoush M., Marques J.T., Gantier M.P., Behlke M.A., John M., Rayman P., et al. Determinants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells. J Interferon Cytokine Res 2008, 28:221-233.
51. Goodchild A., Nopper N., King A., Doan T., Tanudji M., Arndt G.M., et al. Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol 2009, 10:40.
52. Harada Y., Iwai M., Tanaka S., Okanoue T., Kashima K., Maruyama-Tabata H., et al. Highly efficient suicide gene expression in hepatocellular carcinoma cells by epstein-barr virus-based plasmid vectors combined with polyamidoamine dendrimer. Cancer Gene Ther 2000, 7:27-36.
53. Fischer W., Calderon M., Schulz A., Andreou I., Weber M., Haag R. Dendritic polyglycerols with oligoamine shells show low toxicity and high siRNA transfection efficiency in vitro. Bioconjug Chem 2010, 21:1744-1752.
54. Kichler A. Gene transfer with modified polyethylenimines. J Gene Med 2004, 6(Suppl 1):S3-S10.
55. Wagner E., Kircheis R., Walker G.F. Targeted nucleic acid delivery into tumors: new avenues for cancer therapy. Biomed Pharmacother 2004, 58:152-161.
56. Ye W., Ten X., He M., Yu Y., Huang H., Hu Y., et al. Suppression of heart NF-kappaB p65 expression by jugular vein injection of RNAi in mice. Methods Find Exp Clin Pharmacol 2010, 32:391-400.
57. Gunther M., Lipka J., Malek A., Gutsch D., Kreyling W., Aigner A. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm 2011, 77:438-449.
58. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005, 12:461-466.
59. Grzelinski M., Urban-Klein B., Martens T., Lamszus K., Bakowsky U., Hobel S., et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 2006, 17:751-766.
60. Hobel S., Prinz R., Malek A., Urban-Klein B., Sitterberg J., Bakowsky U., et al. Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery. Eur J Pharm Biopharm 2008, 70:29-41.